Lyell Immunopharma annual operating cash flow
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Operating Cash Flow Growth & History (LYEL)
Lyell Immunopharma's operating cash flow was −$150.0M for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$150.0M | $12.4M | — |
| 2024 | 2024-12-31 | −$162.4M | $1.3M | — |
| 2023 | 2023-12-31 | −$163.7M | $5.9M | — |
| 2022 | 2022-12-31 | −$169.6M | −$43.3M | — |
| 2021 | 2021-12-31 | −$126.2M | $34.6M | — |
| 2020 | 2020-12-31 | −$160.9M | −$200.3M | — |
| 2019 | 2019-12-31 | $39.5M | — | — |
Lyell Immunopharma quarterly operating cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$33.9M | $536,000 | — |
| Q1 2026 | 2026-03-31 | −$38.5M | $16.2M | — |
| Q4 2025 | 2025-12-31 | −$32.3M | $15.0M | — |
| Q3 2025 | 2025-09-30 | −$28.6M | $6.5M | — |
| Q2 2025 | 2025-06-30 | −$34.5M | $3.6M | — |
| Q1 2025 | 2025-03-31 | −$54.7M | −$12.7M | — |
| Q4 2024 | 2024-12-31 | −$47.2M | −$6.6M | — |
| Q3 2024 | 2024-09-30 | −$35.0M | $2.6M | — |
| Q2 2024 | 2024-06-30 | −$38.1M | $1.1M | — |
| Q1 2024 | 2024-03-31 | −$42.0M | $4.2M | — |
| Q4 2023 | 2023-12-31 | −$40.6M | −$368,000 | — |
| Q3 2023 | 2023-09-30 | −$37.7M | −$583,000 | — |
| Q2 2023 | 2023-06-30 | −$39.2M | $5.2M | — |
| Q1 2023 | 2023-03-31 | −$46.2M | $1.6M | — |
| Q4 2022 | 2022-12-31 | −$40.3M | −$7.1M | — |
| Q3 2022 | 2022-09-30 | −$37.1M | −$11.6M | — |
| Q2 2022 | 2022-06-30 | −$44.3M | −$10.4M | — |
| Q1 2022 | 2022-03-31 | −$47.9M | −$14.3M | — |
| Q4 2021 | 2021-12-31 | −$33.2M | — | — |
| Q3 2021 | 2021-09-30 | −$25.5M | −$3.9M | — |
| Q2 2021 | 2021-06-30 | −$33.9M | — | — |
| Q1 2021 | 2021-03-31 | −$33.6M | — | — |
| Q3 2020 | 2020-09-30 | −$21.6M | — | — |
Lyell Immunopharma operating cash flow trends
Over the last five fiscal years, Lyell Immunopharma's operating cash flow increased from −$160.9M to −$150.0M, a change of $10.8M. The latest reported quarter, Q2 2026, shows −$33.9M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗